Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by MYSTICALon Aug 01, 2013 3:42pm
394 Views
Post# 21644738

Romney PE firm acquires NHS blood supplier

Romney PE firm acquires NHS blood supplier
Romney PE firm acquires NHS blood supplier

Bain Capital, which used to be led by former US presidential candidate Mitt Romney, has acquired Plasma Resources UK (PRUK) in a £230 million deal..
PRUK is a major blood plasma supplier to the NHS and a government-owned asset.
The private equity house will buy an 80% stake in the business while the government will retain a 20% stake.
PRUK operates two business units: one is Bio Products Laboratory which makes plasma products given by donors at 32 centres operated in the US by PRUK’s other business unit DCI Biological. (UK donors cannot be used due to concerns of transmitting variant Creutzfeldt-Jakob disease.) The company has over 1,200 employees and annual sales are approximately £110 million.
Lazard advised on the sale process, according to Reuters.

Law firm Pinsent Masons and financial advisors Mansfield Partners advised the Department of Health.
 
Sky News reports that a source close to Bain Capital said the firm wanted to create a “UK champion” and would invest in growing the company’s Elstree plant.
After initial reservations about selling a significant supplier of NHS blood, the government announced it would sell the majority of its shares in the company in January 2013.

Louise Fullwood, Legal Director at Pinsent Masons, said: "This deal represents an excellent outcome  for the Department of Health and for the PRUK business – it should allow PRUK to innovate and grow in the sector on a global platform – the deal includes guarantees safeguarding UK jobs and investment. More broadly, we expect this deal to fulfill its potential as part of the strategically important bioscience sector of the UK economy."

Bain is reported to have faced off competition from companies such as German blood plasma specialist Biotest and South Korean drug maker Green Cross Corp.
Bullboard Posts